Company intelligence / Profile preview

Genovax S.r.l.

Ownership: Private
Development stage: Phase 1

Overview

Genovax S.r.l. was an Italian biotechnology company focused on developing synthetic peptide-based therapeutic vaccines, primarily targeting cancers such as kidney neoplasms. Their lead asset, a telomerase peptide cancer vaccine designed to stimulate CD4-positive T lymphocytes, advanced to Phase 2 clinical trials before being discontinued. There are no active programs or recent updates indicating ongoing operations.

Therapeutic areas: Oncology
Modalities: Synthetic peptide vaccinesTherapeutic vaccines
Industry: Biotech

Drug pipeline

2 assets

GX301

Phase 1

Indications: Prostate cancer, Renal cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Genovax S.r.l..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genovax S.r.l..

Explore the full profile